Sustained COVID-19 vaccine willingness in Denmark following the rare cases of blood clots eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
“With an ageing HIV population,” write the investigators, “improvement of survival and quality of life among people living with HIV needs screening for and prevention of non-communicable diseases, including lifestyle changes and use of antiretroviral therapy with minimal toxicity.”
A team of researchers led by Dr Niels Jespersen of Aarhus University Hospital, Denmark, wanted to get a clearer understanding of mortality risk and rates of non-communicable diseases among people living with HIV. They therefore designed a study involving 1043 people with HIV and 1043 HIV-negative controls in central Denmark between 1985 and 2017. The control group was matched on age, sex and municipality, but not on ethnicity, socioeconomic status or lifestyle factors.
Acarix AB: Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
Positive,
long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication.
The long term Prognostic data from the Dan-NICAD 1 trial was first presented at the ESC Congress in September 2019 by Simon Winther, MD, PhD from Aarhus University Hospital, Denmark.
The Dan-NICAD 1 trial was initiated in September 2014 to assess non-invasive methods in patients referred to coronary CTA due to symptoms suggestive of obstructive CAD. Clinically relevant prognostic data were assessed with a median follow-up time of 3 years to evaluate the correlation between CAD-score and prognosis in patients treated by current standard of care.
IRRAS Announces Collaboration with Aarhus University Hospital, Scandinavian Leader in Neurosurgery, to Advance Use of IRRAflow
- The collaboration with Aarhus University s neurosurgical team will evaluate IRRAflow during the treatment of Intraventricular Hemorrhage (IVH) and assessment of brain compliance
News provided by
Share this article
Share this article
STOCKHOLM, April 6, 2021 /PRNewswire/ IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a strategic collaboration with Aarhus University Hospital (AAUH) in Aarhus, Denmark, one of Scandinavia s leading medical institutions.
Dr. Anders Korshøj, Associate Professor of Neurosurgery at Aarhus University Hospital, will lead the collaboration that will unite specialists from the hospital s neurocritical care team and data analytics experts from The Aarhus University Center for Digitalization, Big Data and Data Analytics. The col
06 aprile 2021 13:02
Fonte: Adnkronos
#salute-e-benessere
Simple, Non-Invasive Blood Test Poses No Risk to Pregnant Woman and Fetus; Significantly Safer, More Comprehensive and More Inclusive Compared to Invasive Tissue Sampling Test
Intended for All Pregnant Women, Not Just High-Risk Categories, at 10-14 Weeks of Pregnancy; Earlier Administration Potentially Leading to Higher Confidence and More Individualized Care
Achievement Follows ARCEDI s Prior Non-Invasive Pregnancy Testing Innovations, Including Being the First Company to Identify Extravillous Trophoblasts as the Fetal Cell Types Circulating Within the Maternal Bloodstream
VEJLE, Denmark, April 6, 2021 /PRNewswire/ ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced the launch of EVITA TEST COMPLETE™ (EVITA), the first prenatal genetic blood test to identify and isolate fetal cells in maternal blood. EVITA provides a comple